IBRX – immunitybio, inc. (US:NASDAQ)
Stock Stats
News
Jefferies Lifts ImmunityBio Inc. (IBRX) Price Target Following Anktiva European Expansion [Yahoo! Finance]
ImmunityBio: Anktiva Revenue Will Ramp, But Competitive Risks Remain [Seeking Alpha]
ImmunityBio (NASDAQ:IBRX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer
Should EMA's Conditional Nod for ANKTIVA in High-Risk Bladder Cancer Require Action From ImmunityBio (IBRX) Investors? [Yahoo! Finance]
Form 4 ImmunityBio, Inc. For: Dec 12 Filed by: Wendel Bruce
Form 3 ImmunityBio, Inc. For: Dec 12 Filed by: Wendel Bruce
Form 8-K ImmunityBio, Inc. For: Dec 10
Form 8-K ImmunityBio, Inc. For: Dec 12
Form SCHEDULE 13D/A ImmunityBio, Inc. Filed by: Cambridge Equities, LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.